Biogen, Sangamo collaborate for gene regulation therapies in neurological ailments Medical Dialogues Bureau10 March 2020 9:00 AM ISTBiogen has exclusive global rights to ST-501 for tauopathies including Alzheimer's disease, ST-502 for synucleinopathies including Parkinson's...
More drugmakers including Gilead, Biogen, BMS to hike US prices for 50 drugs Medical Dialogues Bureau2 Jan 2020 2:48 PM ISTNew Delhi: Drugmakers including Bristol-Myers Squibb Co (BMY.N), Gilead Sciences Inc (GILD.O), and Biogen Inc (BIIB.O) hiked U.S. list prices on more...
Roche anticipates USFDA nod for SMA drug Risdiplam by early 2020 Medical Dialogues Bureau26 Nov 2019 9:28 AM ISTRoche, whose drug Risdiplam is seen as a rival for Biogen's Spinraza and Novartis's Zolgensma gene therapy, said the FDA is due to decide by May 24....
Biogen, Alkermes get USFDA nod for multiple sclerosis drug Vumerity Medical Dialogues Bureau31 Oct 2019 9:25 AM ISTThe new drug, Vumerity, was approved to treat relapsing forms of multiple sclerosis, a disabling autoimmune disease that damages the central nervous...
Novartis gets USFDA nod for over Rs 13 crore gene therapy Zolgensma Farhat Nasim25 May 2019 10:00 AM ISTThe Food and Drug Administration on Friday approved the treatment, called Zolgensma, for all children under age 2 who are confirmed by a genetic test...
Bill Gates makes 100 million dollars personal investment to fight Alzheimer Ruby Khatun Khatun15 Nov 2017 10:25 AM ISTLONDON: Billionaire Microsoft co-founder Bill Gates is to invest $50 million in the Dementia Discovery Fund, a venture capital fund that brings...
Roche MS drug Ocrevus wins European panel backing Ruby Khatun Khatun13 Nov 2017 10:02 AM ISTZURICH: Swiss drugmaker Roche on Friday won a key European panel's recommendation for its multiple sclerosis drug Ocrevus, which is on track for...
Regeneron third-quarter profit easily tops Street view on Eylea, Dupixent sales Ruby Khatun Khatun11 Nov 2017 9:30 AM ISTRegeneron Pharmaceuticals Inc on Wednesday reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand...
